The short answer
Biochemical recurrence means a rising PSA, not proven metastatic disease. Doubling time drives urgency, definitions differ after surgery and radiation, and PSMA PET now finds disease earlier.
Biochemical recurrence means a blood test has changed; it is not the same as having metastatic disease found on a scan.
After prostatectomy the usual threshold is a PSA of 0.2 ng/mL or higher, confirmed on a repeat test.
After radiation the standard is a rise of 2 ng/mL or more above the lowest value reached, called the Phoenix definition.
PSA doubling time matters more than any single value: a rise doubling in under six to nine months signals more urgency than a slow climb.
Choose how you want to understand this
The full explanation.
What a rising PSA actually means
After treatment for prostate cancer, PSA is checked periodically. When it starts to rise, that is called biochemical recurrence. It means a blood test has changed. It does not mean cancer has been found anywhere on a scan, and it is not the same thing as metastatic disease.
That distinction is the single most useful thing to hold onto. Biochemical recurrence is a signal that some prostate cells producing PSA are still present somewhere. In many men, those cells never cause symptoms or shorten life. In others they do. Which group you are in is what the next few months of testing are for.
The definitions differ by treatment
After radical prostatectomy, PSA should become essentially undetectable, since the gland is gone. Biochemical recurrence is generally defined as a PSA of 0.2 ng/mL or higher, confirmed on a second test.
After radiation therapy, the prostate is still in place and continues to make some PSA, so an undetectable level is not expected. The standard definition is a rise of 2 ng/mL or more above the lowest value reached, called the nadir. That is the Phoenix definition.
Because the thresholds differ, PSA numbers after surgery and after radiation are not directly comparable, and neither are the timelines.
PSA bounce
After radiation, particularly brachytherapy, PSA sometimes rises temporarily and then falls again on its own. This is called a bounce, it is more common in younger men, and it typically happens within the first two years. It is not recurrence. This is a good reason not to react to one number, and a good reason to ask whether a repeat test is the next step before anything else happens.
PSA doubling time is what drives urgency
Not all rising PSAs behave alike. The most useful measure is how fast it is rising: PSA doubling time, calculated from several values over time.
A slow rise, doubling over many months or years, generally suggests indolent disease and often supports continued monitoring. A rapid rise, doubling in under six to nine months, suggests more aggressive disease and usually prompts faster imaging and treatment discussion. The absolute PSA level matters too, along with your original Gleason grade, surgical margins, and how long after treatment the rise began.
This is why your team may ask you to repeat PSA at intervals rather than acting on the first abnormal value. It is not delay. The trajectory carries more information than any single point.
PSMA PET changed what can be seen
For years, conventional bone scans and CT found almost nothing at low PSA levels, leaving men in an unsatisfying gap where a test was abnormal but imaging was blank.
PSMA PET imaging changed that. These scans use a tracer that binds prostate-specific membrane antigen, and they detect disease at far lower PSA levels than conventional imaging. Gallium-68 PSMA-11 was approved by the FDA in 2020 and piflufolastat F-18 in 2021.
This has real consequences. A PSMA PET may show a single spot amenable to targeted radiation, or nodes that change the plan, or nothing at all. Detection rates rise with higher PSA and faster doubling time, which is why timing the scan matters and why a negative scan at very low PSA does not rule disease out.
What options generally follow
Depending on prior treatment and what imaging shows, the discussion may include salvage radiation to the prostate bed after surgery, salvage local treatment after radiation, targeted treatment of a small number of lesions, hormone therapy, continued monitoring, or a clinical trial. Timing matters: salvage radiation after surgery is generally more effective at lower PSA levels, which is an argument against a long wait-and-see period in higher-risk situations.
There is no single correct answer, and the trade-off between controlling disease and side effects of further treatment is a legitimate part of the decision.
Worth asking
Ask what definition of recurrence your team is using and what your doubling time is. Ask whether a PSMA PET is indicated now or at a higher PSA. Ask what the goal of any proposed treatment is: cure, delay, or symptom prevention. And ask what happens if you do nothing for three months.
Sources
Words to know
Tap any term to see what it means.
Common questions
Does a rising PSA mean the cancer has spread?
No. It means cells producing PSA are still present somewhere. In many men those cells never cause symptoms or shorten life. Imaging and the rate of rise are what distinguish situations that need action from those that do not.
Why is my team asking me to repeat the test instead of acting?
The trajectory carries more information than any single value. Several measurements over time allow PSA doubling time to be calculated, and a temporary bounce after radiation can otherwise be mistaken for recurrence. This is assessment, not delay.
Why is the threshold different after surgery and after radiation?
After prostatectomy the gland is gone, so PSA should be essentially undetectable and 0.2 ng/mL is meaningful. After radiation the prostate remains and keeps producing some PSA, so an undetectable level is never expected and the definition uses a rise above the lowest point reached.
What is a PSMA PET scan and should I have one?
It uses a tracer binding prostate-specific membrane antigen and detects disease at far lower PSA levels than conventional imaging. Gallium-68 PSMA-11 was FDA-approved in 2020 and piflufolastat F-18 in 2021. Detection rates rise with higher PSA and faster doubling time, so timing matters and your team can say whether now or later is more informative.
If nothing shows on the scan, what happens?
A negative scan at low PSA does not rule disease out. Options discussed may include salvage radiation to the prostate bed after surgery, hormone therapy, continued monitoring, or a trial. Timing matters, since salvage radiation after surgery is generally more effective at lower PSA levels.
Questions to ask your doctor
Being prepared helps you get the most out of your appointments. Save or print these questions.
Tap a question to save it to your list (kept on this device).
Speak With Trained Specialists & Human Navigators
Cancer Explained provides educational guidance, but does not replace trained specialists, social workers, or your medical team.
Talk to a trained cancer information specialist
Free, confidential assistance from NCI Cancer Information Service via phone, chat, or email.
Contact your oncology team
Locate after-hours contact numbers, portal messages, or urgent triage phone lines.
Find a patient navigator
Get one-on-one help with appointments, logistics, translation, and care coordination.
Find a genetic counselor
Discuss inherited mutation risk, family history, and genetic testing options.
Find an oncology social worker
Access emotional counseling, family support groups, and mental health resources.
Find a financial navigator
Locate copay assistance foundations, grant programs, and lodging/travel support.
Find a clinical-trial specialist
Search matching studies and speak with NCI trial information specialists.
Get urgent help
Immediate emergency guidance for fever (>100.4°F during chemo), severe pain, or shortness of breath.
Help Us Improve This Guide
Did this explanation answer your question and help you determine your next step?
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Plain-language explanation of the federal sources cited on this page. AI-assisted, source-checked, not clinician-reviewed.
Written by: Cancer Explained Editorial TeamSources last checked: 2026-07-30Last updated: 2026-07-30Next planned review: 2027-07-30
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status — Source verified. This page was created with AI assistance and checked against the sources listed on it. Source checking is not a medical review.
General education — varies by person. Answers genuinely differ between people. This page explains what commonly varies and points you to your care team for your situation.
Human medical review: not completed. Cancer Explained is not clinician-reviewed, and that is a deliberate design choice rather than a gap we are waiting to close. We restate published federal guidance and cite it; the authority belongs to the source, not to us. That is why every page names where its claims come from — so you can verify us instead of trusting us. Use it to understand your situation and to ask better questions of the people treating you.
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status: Source verified — This page was created with AI assistance and checked against the sources listed on it. Source checking is not a medical review.
Human medical review: not completed. Cancer Explained is not clinician-reviewed, and that is a deliberate design choice rather than a gap we are waiting to close. We restate published federal guidance and cite it; the authority belongs to the source, not to us. That is why every page names where its claims come from — so you can verify us instead of trusting us. Use it to understand your situation and to ask better questions of the people treating you.
Read more about our editorial process, our use of AI, and our corrections policy.
Spotted a problem? Report an error — a factual mistake, broken or outdated source, confusing wording, or anything that seems unsafe. Please do not include names, medical record numbers, dates of birth, addresses, or other identifying medical information in your report.
After using this page, do you understand what to do next?
Anonymous — we only record the answer, never who gave it.
Related articles
Still have questions?
Educational answers, plain language
Free to print and share